The serotonin membrane transporter is one of the main mechanisms of plasma serotonin concentration regulation. Serotonin plays an important role in the pathogenesis of various cardiovascular diseases, stimulating the proliferation of smooth muscle cells, key cells in the process of hypertrophic vascular remodeling. Vascular remodeling is one of the leading prognostically unfavorable factors of atherosclerosis, the main manifestation of familial hypercholesterolemia. Familial hypercholesterolemia is one of the most common genetically determined lipid metabolism disorders and occurs in 1 in 313 people. The aim of our study was to investigate the levels of plasma and platelet serotonin, 5-hydroxyindoleacetic acid, and membrane transporter in a cross-sectional study of two pediatric groups, including patients with familial hypercholesterolemia and the control group, which consisted of apparently healthy children without cardiovascular diseases. The study involved 116 children aged 5 to 17 years old. The proportion of boys was 50% (58/116) and the average age of the children was 10.5 years (CI 2.8–18.1). The concentrations of serotonin in blood plasma and platelets and 5-hydroxyindoleacetic acid were higher in children with familial hypercholesterolemia than in the controls. The concentration of the serotonin transporter in platelets in healthy children, compared with the main group, was 1.3 times higher. A positive correlation was revealed between the level of serotonin (5-HT and PWV: ρ = 0.6, p < 0.001), its transporter (SERT and PWV: ρ = 0.5, p < 0.001), and the main indicators of arterial vascular stiffness. Our study revealed the relationship between high serotonin and SERT concentrations and markers of arterial stiffness. The results we obtained suggest the involvement of serotonin and SERT in the process of vascular remodeling in familial hypercholesterolemia in children.
Cardiovascular diseases are the leading cause of disability and mortality worldwide. Cardiovascular mortality rate is steadily increasing despite the large-scale preventive measures. Familial hypercholesterolemia is the most common genetically determined disorder of lipid metabolism as the major cause of blood circulatory system diseases development and progression. Worldwide, there are 6.8–8.5 million children with this primary dyslipidemia. Early (in childhood) diagnosis of familial hypercholesterolemia is crucial for the timely initiation of lipid-lowering therapy in order to reduce the atherosclerosis progression and the risk of life-threatening cardiovascular events. New screening programs have been implemented, new biomarkers of the disease have been studied, and lipid-lowering drugs with new mechanisms of hypolipidemic action have been developed to increase the efficacy of these activities in economically developed countries.
Familial hypercholesterolemia leads to the early development of cardiovascular diseases at a young age due to the prolonged exposure of the arterial vessel wall to high concentrations of atherogenic lipids. Serotonin plays a significant role in the development and progression of atherosclerotic processes. Monoamine has a damaging effect on the vascular wall, stimulates the proliferation of vascular smooth muscle cells and fibroblasts, and participates in platelet activation and aggregation. The aim of the work was the demonstration of the importance of serotonin, transporters, and receptors in the pathogenesis of atherosclerotic plaque formation. The study was performed on immature mice of the C57BL/6JGpt-Ldlrem1Cd82/Gpt (Ldlr+/−) line (main group) and C57BL/6 mice of comparable age and sex demographics (control group). Morphological manifestations of early signs of atherosclerosis (pre-lipid stage and lipoidosis stage, which were confirmed by Sudan III staining) in the gene-modified mice’s aorta were determined. Morphological changes in the aorta correlated with changes in the left ventricle of the heart, where lipid content also increased. No atherosclerotic changes in the control-group mice were detected. A statistically significant increase in the expression of the membrane serotonin transporter and 5HT2A and 5HT2B receptors in both the aorta and left ventricle was also found in the animals of the main group. Serotonin and its receptors and transporter may become new therapeutic targets for the treatment and prevention of atherosclerotic vascular lesion progression in children and adults.
Familial hypercholesterolemia (FH) is the leading cause of premature cardiovascular disease and the most common disorder of lipid metabolism in childhood. Early diagnosis of FH and an effective patient monitoring strategy are extremely promising for reducing the risk of atherosclerosis in the future. Aim. Conduct and analyze the results of cascade screening along the childparent path for the diagnosis of FH. Materials and methods. The study was carried out in the period from December 2018 to August 2021 on the basis of Children's Republican Clinical Hospital, City Clinical Hospital No.7 in Kazan, Kazan State Medical University. Inclusion criteria: age 017 years inclusive, diagnosed with Heterozygous form of familial hypercholesterolemia in accordance with clinical guidelines according to the criteria of the Simon Broome Registry, informed consent for participation in the study of children and/or their parents. Exclusion criteria: underlying diseases/conditions, as well as drugs that may cause a secondary increase in low-density lipoprotein cholesterol. Results. During this period, 34 children were identified with a diagnosis of heterozygous FH (mean age 8.73.6 years). After further examination of relatives, FH was diagnosed in 33 parents, 15 siblings, 56 relatives of the 2nd line of relationship. The average age of the parents was 384.3 years. In 20 (60.6%) of them ischemic heart disease was diagnosed, in 18 (54.5%) atherosclerosis of the brachiocephalic arteries. In addition, 10 (30%) patients required coronary angiography, 3 (9%) coronary artery bypass grafting, 2 (6%) stenting of coronary vessels. Conclusion. The diagnostic result of the cascade screening along the childparent path was 3 new cases of FH per one child-proband.
27 December 2024 in Ulyanovsk Medico-biological Journal
Dopamine is an endogenous catecholamine and its effects are not limited to the central nervous system. Thus, dopamine affects the gastrointestinal motility, hormone release, and sodium balance. Recently, the role of peripheral dopamine in regulating cardiac functions has been studied by various scientists. The aim of the review is to summarize the currently available data on the role of dopamine in cardiac regulation. Materials and Methods. Papers from PubMed, Google Scholar, and eLIBRARY.RU were analyzed for the literature review. Results. Dopamine, being an agonist of cardiac α- and β-adrenergic receptors, has positive chronotropic and inotropic cardiac effects. In proximal arteries, catecholamine causes dose-dependent contraction, whereas in distal arteries, low dopamine concentration leads to dilation, while high concentration causes contraction. Due to the wide variety of receptors, dopamine has a cardioprotective effect, reducing cardiac hypertrophy and fibrosis. Experimental studies with laboratory animals have shown that catecholamine suppresses inflammation mediated by NLRP3 inflammasome activation in cardiomyocytes, and reduces IL-6 and endothelin-1 release. Dopamine plays an important role in the pathogenesis of hypertension by regulating epithelial sodium transport and interacting with vasoactive hormones/humoral factors such as aldosterone, angiotensin, renin, and vasopressin. Dopamine may also have a negative cardiac effect. Use of a dopamine-adrenergic receptor agonist increases mortality risk among patients with advanced heart failure. High level of free catecholamine is an independent risk factor for future coronary events in patients with coronary heart disease. Conclusion. Dopamine plays a special role in cardiac regulation. However, further studies are desirable, as it is necessary to examine the changes in the catecholamine concentration in various cardiac pathologies. In the future, it will contribute to the development of effective diagnostic, preventive and therapeutic measures.
9 December 2021 in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
Objective. To describe a case of atrial flutter in a newborn.Results. The child in the maternity hospital was found to have a heart rhythm disorder of the type: atrial flutter, constant form. Examination revealed an atrial septal defect and an increase in the level of natriuretic peptide. Subsequently, the child was diagnosed with atrial flutter, constant form. NK 0-1. Open oval window. Treatment with drugs from the group of antiarrhythmics, antioxidants and cardiac glycosides made it possible to avoid pronounced hemodynamic disorders.Conclusion. The presented case demonstrates that timely diagnosis and medical correction prevent possible complications.